Dapagliflozin and cardiovascular outcomes in type 2 diabetes

S. D. Wiviott, I. Raz, M. P. Bonaca, O. Mosenzon, E. T. Kato, A. Cahn, M. G. Silverman, T. A. Zelniker, J. F. Kuder, S. A. Murphy, D. L. Bhatt, L. A. Leiter, D. K. McGuire, J. P.H. Wilding, C. T. Ruff, I.A.M. Gause-Nilsson, M. Fredriksson, P. A. Johansson, A. M. Langkilde, M. S. SabatineDECLARE–TIMI 58 Investigators, P. Aylward, B. Lewis, S. Stranks, R. Lehman, A. Hamilton, R. Shah, J. Wood

Research output: Contribution to journalArticlepeer-review

1543 Citations (Scopus)

Fingerprint Dive into the research topics of 'Dapagliflozin and cardiovascular outcomes in type 2 diabetes'. Together they form a unique fingerprint.

Medicine & Life Sciences